154 related articles for article (PubMed ID: 35653034)
41. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Jan; 34(1):246-253. PubMed ID: 32870449
[TBL] [Abstract][Full Text] [Related]
42. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
[TBL] [Abstract][Full Text] [Related]
43. Reliability and Role of Mutation-specific H3F3A (Histone 3-3) G34W Immunohistochemistry to Differentiate Giant Cell Tumor of Bone From its Clinicoradiologic and Histologic Mimics: An Institutional Study.
Pasricha S; Pruthi M; Jajodia A; Kumar A; Gupta G; Sharma A; Tiwari A; Rohela H; Durga G; Kamboj M; Koyyala VPB; Mehta A
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):36-41. PubMed ID: 34347625
[TBL] [Abstract][Full Text] [Related]
44. p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.
Okubo T; Saito T; Mitomi H; Takagi T; Torigoe T; Suehara Y; Kaneko K; Yao T
Virchows Arch; 2013 Jul; 463(1):67-77. PubMed ID: 23748877
[TBL] [Abstract][Full Text] [Related]
45. Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1.
Oyama R; Kito F; Qiao Z; Sakumoto M; Shiozawa K; Toki S; Yoshida A; Kawai A; Kondo T
In Vitro Cell Dev Biol Anim; 2019 Jan; 55(1):62-73. PubMed ID: 30411273
[TBL] [Abstract][Full Text] [Related]
46. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
[TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.
Balla P; Maros ME; Barna G; Antal I; Papp G; Sapi Z; Athanasou NA; Benassi MS; Picci P; Krenacs T
PLoS One; 2015; 10(5):e0125316. PubMed ID: 25933380
[TBL] [Abstract][Full Text] [Related]
48. Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Sei A; Takeshita F; Sugaya J; Nakatani F; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Sep; 34(5):1569-1578. PubMed ID: 34164773
[TBL] [Abstract][Full Text] [Related]
49. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.
Noh BJ; Park YK
Hum Pathol; 2018 Nov; 81():1-8. PubMed ID: 29944971
[TBL] [Abstract][Full Text] [Related]
50. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
51. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Sin Y; Ono T; Sugaya J; Iwata S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2021 Nov; 34(6):1911-1918. PubMed ID: 34383271
[TBL] [Abstract][Full Text] [Related]
52. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone.
Chen F; Wang S; Wei Y; Wu J; Huang G; Chen J; Shi J; Xia J
Biomed Pharmacother; 2018 Jul; 103():1092-1100. PubMed ID: 29710674
[TBL] [Abstract][Full Text] [Related]
53. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Kito F; Sei A; Sugaya J; Nakagawa M; Yoshida A; Iwata S; Kawai A; Kondo T
Hum Cell; 2020 Apr; 33(2):427-436. PubMed ID: 31898195
[TBL] [Abstract][Full Text] [Related]
54. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
55. Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma.
Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Sato C; Kobayashi E; Kojima N; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 Nov; 35(6):1993-2001. PubMed ID: 35947340
[TBL] [Abstract][Full Text] [Related]
56. Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Sugaya J; Fukushima S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2020 Oct; 33(4):1302-1310. PubMed ID: 32648033
[TBL] [Abstract][Full Text] [Related]
57. Correction to: Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone.
Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Fukushima S; Toda Y; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2023 Jan; 36(1):492. PubMed ID: 36258092
[No Abstract] [Full Text] [Related]
58. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing.
Lim J; Park JH; Baude A; Yoo Y; Lee YK; Schmidt CR; Park JB; Fellenberg J; Zustin J; Haller F; Krücken I; Kang HG; Park YJ; Plass C; Lindroth AM
Sci Rep; 2017 Oct; 7(1):13459. PubMed ID: 29044188
[TBL] [Abstract][Full Text] [Related]
59. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Nakagawa M; Yoshida A; Kawai A; Kondo T
Hum Cell; 2020 Jul; 33(3):894-903. PubMed ID: 32356243
[TBL] [Abstract][Full Text] [Related]
60. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
